Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test
Analysts Skeptical About Taking On Established Players
Moderna's long-term strategy is to combine its COVID=19, flu and RSV shots in one - but proving efficacy against competitors will be a challenge. • Source: JOSEPH PREZIOSO/AFP via Getty Images (JOSEPH PREZIOSO/AFP via Getty Images)
